论文部分内容阅读
目的观察康艾注射液对非小细胞肺癌(NSCLC)化疗患者近期疗效及免疫功能的影响。方法将98例(NSCLC)患者随机分为对照组和观察组,每组各49例。对照组采用长春瑞滨+顺铂或吉西他滨+顺铂方案进行化疗;观察组在对照组治疗基础上加用康艾注射液,比较两组的近期疗效及CD3+、CD4+、CD8+、CD4+/CD8+和NK细胞的变化。结果治疗组近期临床总有效率为42.9%,略高于对照组的36.7%,但组间差异无统计学意义(P>0.05)。与对照组比较,化疗后观察组CD3+、CD4+和NK细胞百分数显著高于对照组,CD8+百分数显著低于对照组,CD4+/CD8+比值显著高于对照组,组间差异均有统计学意义(P<0.05)。结论康艾注射液可提高NSCLS患者的近期疗效和机体免疫力。
Objective To observe the effect of Kangai injection on the short-term curative effect and immune function of patients with non-small cell lung cancer (NSCLC) chemotherapy. Methods 98 patients (NSCLC) were randomly divided into control group and observation group, 49 cases in each group. The control group was treated with vinblastine + cisplatin or gemcitabine plus cisplatin. The observation group was given Kang Ai injection on the basis of the control group, and the short-term curative effect and the ratio of CD3 +, CD4 +, CD8 +, CD4 + / CD8 + NK cell changes. Results The total clinical effective rate in the treatment group was 42.9%, slightly higher than that in the control group (36.7%), but there was no significant difference between the two groups (P> 0.05). Compared with the control group, the percentage of CD3 +, CD4 + and NK cells in the observation group after chemotherapy was significantly higher than that in the control group, the percentage of CD8 + was significantly lower than that in the control group, and the ratio of CD4 + / CD8 + was significantly higher than that in the control group <0.05). CONCLUSION Kang’ai injection can improve the short-term curative effect and immunity of patients with NSCLS.